The commonest cutaneous adverse reaction to PD1 inhibitors was vitiligo (four patients), followed by eczema exacerbation (three patients), lichenoid dermatitis (two patients), psoriasiform eruption (one patient) and exanthem (one patient) (Table 5). This evidence concerns the gene PDCD1 and Eczematoid dermatitis.